The rise of Sildenafil initially sparked a period of growth for major pharmaceutical companies, but recent shifts present a complicated outlook for shareholders. Lower-cost alternatives are eating into profits, and https://brendarmem865654.theideasblog.com/41652783/sildenafil-and-big-pharma-a-risky-bet